These companies will be among those sharing information and data in Boston, Massachusetts November 14-16, 2023.
The 4th Annual Dry AMD Therapeutic Development conference is set to take place in Boston, Massachusetts on November 14 through 16, 2023. At this event, companies will share their recent data and research on the subject of dry age-related macular degeneration (AMD). Among those set to present are Akari Therapeutics and Nanoscope Therapeutics.
Chief Scientific Officer, Miles Nunn, will present a poster titled Development of PASylated®-Nomacopan for Treatment of Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (dAMD). The poster will be presented on November 15, 2023 at 3:00 pm ET. The company has shared ahead of the conference tha long-acting PAS-nomacopan is a bispecific inhibitor of complement C5 and leukotriene B4 (LTB4). It is in the final stages of pre-clinical development as a potential treatment for GA.1
During the conference, Samarendra Mohanty, MD, Nanoscope’s President and Chief Scientific Officer, will participate in a panel and present. Mohanty will be on the panel discussion titled, “Overcoming the Limitations of Dry AMD not having a Recognized Disease Model” on November 15, 2023 at 11:00 am ET.2
The following day, Mohanty will present on the prospect of optogenetics to improve visual acuity in macular degeneration patients from proof-of-concept data obtained in humans and discuss the platform's potential to treat different retinal degenerative conditions. This presentation will take place on November 16, 2023 at 4:00 pm ET.2